Sign in
Taking people in United StatesPhase 2

Comparing a BTK inhibitor alone with BTK inhibitor plus venetoclax in leukemia

Compares a BTK inhibitor pill alone with that pill plus venetoclax in CLL.

Key facts

Who runs it
VA Office of Research and Development
Where
Durham, Kansas City, San Francisco, and Seattle, United StatesSee the 4 sites
Trial code
Registry title
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
1 Oct 2025
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Venetoclax
  • Ibrutinib, Acalabrutinib, Zanubrutinib
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have taken a BTK inhibitor pill for at least six months and still have detectable disease.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
CLL or SLL that can still be detected in the blood or on imaging. Low risk of tumor lysis syndrome: all lymph nodes under 5 cm (2 in) and lymphocyte count under 25 x 109/L. ECOG performance status 0-2.
Earlier treatment
Must be taking a BTK inhibitor (ibrutinib, acalabrutinib or zanubrutinib) for at least six months, at a stable dose for at least the past three months. Must not have had the BTKi plus venetoclax combination before.

Main reasons for not taking part

  • CLL or SLL that got worse while on BTK inhibitor treatment
  • History of Richter's transformation or prolymphocytic leukemia
  • Taking heparin or warfarin as a blood thinner
  • Needing more than 20 mg prednisone (or equivalent) a day
  • Active infection needing antibiotics through a vein

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) diagnosis
  • Patients must have been diagnosed with CLL (> 5000 B-cells per microliter of peripheral blood at any point during the course of their disease) or small lymphocytic lymphoma (SLL) with <5000 B-cells per microliter of blood but with disease-associated lymphadenopathy by 2018 IWCLL criteria
  • Prior treatment
  • Patients must be currently receiving CLL/SLL directed therapy with a BTKi (i.e., ibrutinib, acalabrutinib, zanubrutinib) for at least six months
  • The dose of Bruton Tyrosine Kinase Inhibitor (BTKi) must be stable for at least the past three months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Detectable or measurable CLL/SLL in blood or imaging during the screening period. Detectable CLL/SLL in the blood is defined either by elevation in absolute lymphocyte count or by diagnostic flow cytometry from blood demonstrating presence of CLL cells
  • Low Tumor Lysis Syndrome (TLS) risk, defined as having all lymph nodes less than 5 centimeters (cm) in diameter (radiographically) and absolute lymphocyte count less than 25 x 109/liter (L) in blood, within 30 days of enrollment
  • Required initial laboratory values
  • Absolute Neutrophil Count (ANC) 1,000/ cubic millimeters (mm3) except if due to bone marrow involvement
  • Platelet Count (untransfused) 30,000/cubic millimeters (mm3) except if due to bone marrow involvement
  • Calc. Creatinine Clearance 40 milliliters per minute (mL/min) (by Cockcroft-Gault)
  • Bilirubin 1.5 x upper limit of normal (ULN) except if due to liver involvement, hemolysis, or Gilbert's disease
  • Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) 2.5 x upper limit of normal (ULN) except if due to liver involvement
  • Other
  • Patients must be able to swallow oral medications and not have the following conditions: disease significantly affecting gastrointestinal absorption, resection of the stomach or small bowel, partial or complete bowel obstruction
  • Patients must be able to receive either a xanthine oxidase inhibitor or rasburicase

Who cannot take part

  • Prior treatment
  • Patients must not have progression of CLL/SLL on Bruton Tyrosine Kinase Inhibitor (BTKi) therapy prior to initiation of the study therapy
  • Patients must not have received the combination of Bruton Tyrosine Kinase Inhibitor (BTKi)+ venetoclax previously
  • Please note: Intravenous immunoglobulin (IVIG) can cause a false positive hepatitis B serology. If patients receiving routine IVIG have core antibody or surface antigen positivity without evidence of active viremia (negative hepatitis B DNA) they may still participate in the study, must have hepatitis serologies and hepatitis B DNA monitored periodically by the treating physician
  • If history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load
  • Concomitant medications
  • Patients must not be receiving active systemic anticoagulation with heparin or warfarin. Patients on warfarin must discontinue the drug for at least 10 days prior to registration on the study
  • Chronic concomitant treatment with strong inhibitors of CYP3A4/5 is not recommended on this study. Patients on strong CYP3A inhibitors must discontinue the drug for 14 days prior to registration on the study or discuss with the study principal investigator
  • Chronic concomitant treatment with strong CYP3A4/5 inducers is not recommended. Patients must discontinue the drug 14 days prior to registration on the study or discuss with the study principal investigator
  • Patients must not require more than 20 milligrams (mg) prednisone or equivalent corticosteroid daily
  • Comorbid conditions or other active diseases
  • Patients must not have any history of Richter's transformation or prolymphocytic leukemia
  • If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable and be on suppressive therapy, if indicated
  • Patients with Class III or Class IV heart failure by New York Heart Association, those with unstable angina, and those with uncontrolled arrhythmia are not eligible
  • Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy are eligible for this trial
  • Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Durham VA Medical Center, Durham, NCDurham, United StatesContact: Daphne Friedman, MDTaking people
  • Kansas City VA Medical Center, Kansas City, MOKansas City, United StatesContact: Murali K Nittala, MBBS MS MDTaking people
  • San Francisco VA Medical Center, San Francisco, CASan Francisco, United StatesContact: Gerald Hsu, MDTaking people
  • VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Jeannine BartonTaking people

About the trial

What the trial wants to find out

People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax.

Read full original descriptionShow less

The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.

The 2 groups in the trial

  • Arm A : Continue BTKi single agentExisting treatment, for comparison

    Continue BTKi single agent (monotherapy) Standard Intervention

    Treatment: Ibrutinib, Acalabrutinib, Zanubrutinib

  • Arm B : BTKi + Venetoclax for 12 cycles, then discontinueTreatment being tested

    BTKi + Venetoclax for 12 cycles, then discontinue Experimental Intervention

    Treatment: Venetoclax and Ibrutinib, Acalabrutinib, Zanubrutinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Plain-language title
Comparing a BTK inhibitor alone with BTK inhibitor plus venetoclax in leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06520098, who can take part
Record updated
30 October 2026